ESALY.PK

Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting

Retrieved on: 
Thursday, November 24, 2022
Adolescence, Epilepsy, III, AES, Poster, Patient, Neurology, Perampanel, Eisai, Disease, FOS, AED, Olex, Senior, Seizure, Ageing, AMPA, Safety, Pharmaceutical industry

Perampanel is a first-in-class AED discovered by Eisai's Tsukuba Research Laboratories.

Key Points: 
  • Perampanel is a first-in-class AED discovered by Eisai's Tsukuba Research Laboratories.
  • Eisai considers neurology, including epilepsy, a therapeutic area of focus.
  • Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy.
  • Eisai remains committed further to addressing the diverse needs of, and increasing the benefits provided to, patients with epilepsy and their families

To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research

Retrieved on: 
Tuesday, November 22, 2022
Cosmos, Amyloid, Self-assessment, Dementia, Diagnosis, PET, Oita University, Attention, MCI, Blood, Ministry, Brain, Physician, AD, Patient, Scientific method, Faculty, Medical school, Cerebrospinal fluid, Department of Neurology, Xuanwu hospital, Shimadzu, Research, Ecosystem, Memory, Amyloid beta, Ministry of Health, Labour and Welfare, CSF, Medical imaging, Health, Eisai, Alzheimer's disease, Neurology, Medicine

This joint study will attempt to develop Japan's first diagnostic workflow for mild cognitive impairment (MCI) and Alzheimer's disease (AD) that uses blood biomarkers.

Key Points: 
  • This joint study will attempt to develop Japan's first diagnostic workflow for mild cognitive impairment (MCI) and Alzheimer's disease (AD) that uses blood biomarkers.
  • Usuki City Medical Association will recruit applicants (50 years and older) who wish to participate in the study.
  • Primary care physicians affiliated with Usuki City Medical Association will perform simple cognitive function tests on applicants and select around 200 people with suspected MCI or mild dementia.
  • With this joint research, the four parties aim to establish a new diagnostic workflow for Alzheimer's disease that is based on blood biomarkers and includes primary care physicians.

Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer's Disease Research at The 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Retrieved on: 
Monday, November 21, 2022
Incidence, MCI, PMDA, Medicines and Healthcare products Regulatory Agency, Food, Safety, Brain, Prescription Drug User Fee Act, AD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Clinical trial, Priority review, Pharmaceuticals and Medical Devices Agency, Faculty, Research, ARIA, Amyloid-related imaging abnormalities, Trial of the century, PDUFA, Poster, FDA, BLA, Pharmaceutical industry, Medical imaging, Eisai, Disease, Clarity, Alzheimer's disease

Additionally, other important research from the lecanemab clinical development program and Eisai's AD pipeline, including the company's investigational anti-microtubule binding region (MTBR) tau antibody (E2814), will be presented in four oral and ten poster presentations.

Key Points: 
  • Additionally, other important research from the lecanemab clinical development program and Eisai's AD pipeline, including the company's investigational anti-microtubule binding region (MTBR) tau antibody (E2814), will be presented in four oral and ten poster presentations.
  • - Clarity AD: Full results from the Phase 3 confirmatory Clarity AD clinical trial of lecanemab in patients with early AD will be presented in a scientific session on November 29 at 4:50 p.m. PT.
  • Eisai will host a live webcast of presentations in the session and can be viewed live on the investors section of the Eisai Co., Ltd. website.
  • The FDA has agreed that the results of Clarity AD can serve as the confirmatory study to verify the clinical benefit of lecanemab.

Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis

Retrieved on: 
Wednesday, November 16, 2022
Marketing, Gesellschaft mit beschränkter Haftung, Patient, Medac, MTX, Rheumatoid arthritis, Senior, Gemeinschaft and Gesellschaft, Safety, Pharmaceutical industry, Eisai, Methotrexate

TOKYO, Nov 16, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan with the indication of rheumatoid arthritis.

Key Points: 
  • TOKYO, Nov 16, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan with the indication of rheumatoid arthritis.
  • nippon medac obtained the manufacturing and marketing approval of Japan's first self-administrable subcutaneous injection formulation of MTX, a first line option for the treatment of rheumatoid arthritis, on September 26, 2022.
  • "Eisai has established a solid franchise and has extensive sales experience in the rheumatoid arthritis area in Japan.
  • It is also the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan," said Hirohisa Iriyama, Representative Director and President of nippon medac.

Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH

Retrieved on: 
Monday, November 7, 2022
ALA, Technology, United Nations Global Compact, Growth, DKSH, SIX Swiss Exchange, Vertigo, Neurology, Eisai, OTC, E-commerce, Marketing, Eperisone, Final good, Patient, Pharmaceutical industry, Tutoring

Eisai believes that this divestiture agreement will accelerate the pursuit of the best marketing mix in the ALA Region.

Key Points: 
  • Eisai believes that this divestiture agreement will accelerate the pursuit of the best marketing mix in the ALA Region.
  • Under the terms of the agreement, Eisai will receive a contractual up-front payment, and also plan to supply the products.
  • Eisai will retain its manufacturing rights to and continue to distribute the products in countries such as Japan, China and South Korea.
  • *Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines (Myonal only), Singapore, Taiwan (Merislon only), Thailand
    DKSH's purpose is to enrich people's lives.

Eisai's Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer's Disease, in Thailand

Retrieved on: 
Friday, November 4, 2022
Alzheimer's disease, Life, Patient, Income, Ageing, Awareness, Disease, Insurance, Diagnosis, Thai Life Insurance, Dementia, Residential care, Eisai

TOKYO, Nov 4, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co. Ltd. ("Eisai Thailand") made an agreement to collaborate in supporting access to treatments for dementia, including Alzheimer's disease, in Thailand with Thai Life Insurance Public Company Limited, a leading life insurance company in Thailand.

Key Points: 
  • TOKYO, Nov 4, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co. Ltd. ("Eisai Thailand") made an agreement to collaborate in supporting access to treatments for dementia, including Alzheimer's disease, in Thailand with Thai Life Insurance Public Company Limited, a leading life insurance company in Thailand.
  • In Thailand, the number of people suffering from dementia is expected to increase significantly from the current 600 thousand to 1.1 million by 2030 due to the rapid aging of the population(1), and the financial burden of the people suffering from dementia, including Alzheimer's disease, and their families due to care is also expected to increase.
  • With this agreement, Eisai Thailand, together with Thai Life Insurance, which has expertise in the design and development of life and medical insurance products, will work together to design insurance products to cover dementia, including Alzheimer's disease raise awareness of the disease, and build a dementia ecosystem to secure access to next-generation Alzheimer's disease treatments in Thailand.
  • Eisai believes that it is Eisai's mission to ensure that patients in need have access to its innovative medicines, and will continue to focus on activities for early consultation and diagnosis, as well as development of patient support programs that take into account the healthcare system and income level of each country.